- Home
- Products
SYNRIBO (Omacetaxine Mepesuccinate)
SYNRIBO (Omacetaxine Mepesuccinate)
- Medicine Name: Synribo
- Generic Name: Omacetaxine Mepesuccinate
- Dosage Form & Strength: Single-use vial containing 3.5 mg lyophilized powder for injection
- Manufactured By: Teva Pharmaceuticals USA, Inc.
Synribo (omacetaxine mepesuccinate) is an anticancer medication indicated for the treatment of chronic or accelerated phase chronic myeloid leukemia (CML) in adult patients who have demonstrated resistance and/or intolerance to two or more tyrosine kinase inhibitors (TKIs).
FDA Approval:
Synribo was approved by the U.S. FDA in August 2015 for use in CML patients with limited treatment options due to TKI failure or intolerance.
Form & Dosage:
Available as a single-use vial containing 3.5 mg of omacetaxine mepesuccinate (lyophilized powder for reconstitution and subcutaneous injection).
Treatment regimens are individualized based on patient condition and phase of CML and must be administered by a trained healthcare professional.
- Bone Marrow Suppression: Synribo can cause severe thrombocytopenia, neutropenia, and anemia. Frequent complete blood counts (CBC) are essential.
- Infection Risk: Patients are at increased risk for infections due to low white blood cell counts. Monitor closely and treat any infections promptly.
- Bleeding Risk: Reduced platelet levels may cause unusual bruising or bleeding. Report any bleeding events immediately.
- Injection Site Reactions: Common reactions include redness, swelling, or discomfort at the injection site.
- Pregnancy Risk: Synribo can harm an unborn baby. Effective contraception is required during treatment.
- Breastfeeding: It is not known whether Synribo passes into breast milk. Breastfeeding is not advised during therapy.
- Gastrointestinal Distress: Nausea, vomiting, and diarrhea are possible and should be managed symptomatically.
To Import Synribo into India, the following documents are required:
- Valid prescription from a licensed oncologist
- Patient’s diagnostic reports
- Government-issued photo ID of the patient
Order Confirmation:
Orders will only be processed upon receipt of all the above documentation and an import permit, if required by authorities.
Availability in India:
Synribo is not commercially available in Indian pharmacies. GlobalRareMeds assists patients in India with access to Synribo under the Named Patient Import Program, sourcing it from certified international suppliers.
GlobalRareMeds sources Synribo (Omacetaxine Mepesuccinate) from licensed distributors across the USA, Canada, and Europe.
Orders are fulfilled via our Ambernath, Thane District fulfillment center and dispatched to all major Indian cities, including Mumbai, Delhi, Bengaluru, Chennai, Hyderabad, Ahmedabad, Kolkata, Pune, and more.
To place an order or get pricing details, contact us at:
📧 info@globalraremeds.com
📞 +91-99675 15602
📱 WhatsApp: +91-99675 15602
What is the generic name of Synribo?
Omacetaxine Mepesuccinate.
Who manufactures Synribo?
Synribo is manufactured by Teva Pharmaceuticals USA, Inc.
What is Synribo used for?
Synribo is indicated for adult patients with chronic or accelerated phase Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML) who are resistant or intolerant to two or more tyrosine kinase inhibitors.
Is Synribo FDA approved?
Yes, Synribo was approved by the U.S. FDA in August 2015.
What are the common side effects of Synribo?
Common side effects include low blood cell counts, injection site reactions, nausea, diarrhea, fatigue, fever, and infections.
How do I get Synribo in India at the best price?
You can legally import Synribo through GlobalRareMeds. Contact us with your prescription for pricing and assistance.
Is Synribo available in SAARC or Gulf countries?
Yes, we also facilitate supply to countries including Nepal, Bangladesh, Sri Lanka, UAE, Bahrain, and more.
Is it safe to buy Synribo online in India?
Yes, when purchased via a regulated and authorized channel like GlobalRareMeds under the Named Patient Program.
What are the storage requirements for Synribo?
Store Synribo refrigerated at 2°C–8°C (36°F–46°F). Do not freeze. Keep in the original carton to protect from light.
Contact Patient Support
If you have questions about your order, need assistance with documentation, or require support with medicine availability, our GlobalRareMeds Patient Support Team is here to help. We aim to respond within 24 hours, Monday to Friday, between 9:00 AM and 10:00 AM IST.
info@globalraremeds.com
Phone
+91 99675 15602
+91 99675 15602
Disclaimer
All trademarks, brands, and product names featured on this website are the property of their respective owners. GlobalRareMeds does not claim ownership or affiliation unless explicitly stated. Our role is to provide reliable and transparent access to difficult-to-source medicines through named-patient import services, based on valid prescriptions and legal requirements.
The product-related content on this website is shared to the best of our knowledge, compiled from publicly available sources and regulatory documents. However, GlobalRareMeds does not guarantee the accuracy, completeness, or timeliness of this information. We strongly recommend that all medical decisions, including usage and dosage, be made only in consultation with the prescribing doctor. GlobalRareMeds assumes no responsibility for consequences arising from reliance on this information without appropriate medical guidance
